Skip to content
Search

Latest Stories

Blood tests for Alzheimer's diagnosis could be available on NHS within five years

These tests can diagnose Alzheimer’s disease earlier and more accurately than current methods 

 A £5m project has been launched to introduce new blood tests in the National Health Service (NHS) that can diagnose Alzheimer’s disease.


The blood tests could be available on the NHS within five years and they can diagnose the disease earlier and more accurately than current methods, experts have said.

Alzheimer’s Research UK, the Alzheimer’s Society and the National Institute of Health and Care Research have jointly launched the project.

Susan Kohlhaas, Executive Director of Research and Partnerships at Alzheimer’s Research UK, said that the NHS doesn’t possess the “required levels of diagnostic infrastructure” to cope with the “growing demand” for dementia diagnosis.

“Low-cost tools like blood tests that are non-invasive and simpler to administer than current gold standard methods are the answer to this,” she added.

Fiona Carragher, Director of Research and Influencing at the Alzheimer’s Society, said implementing a blood test for dementia into UK healthcare systems would be “a truly game-changing win in the fight against this devastating disease.”

Diagnosis of Alzheimer’s to become easier

According to Kohlhaas, diagnosis of Alzheimer’s is currently done through brain imaging or lumbar punctures that can be “invasive and come with uncomfortable side effects.”

Lumbar puncture is a process of diagnosis in which a sample of spinal fluid is drawn from the lower back.

The 2023 Dementia Attitudes Monitor survey also revealed that blood tests for diagnosing dementia would be much more acceptable to the public than the existing tests.

More than half of UK adults would be reluctant to undergo a lumbar puncture, but over 90 per cent of respondents would be willing to take a blood test, the survey found.

Several blood tests for Alzheimer’s are currently in the research stages. Some of these look for specific proteins, such as amyloid and tau, that occur before dementia symptoms appear.

However, so far, no test has been clinically validated in the UK, or made available to patients in the NHS.

Funds for the new project have been raised by players of People’s Postcode Lottery, and it will involve working with world-class researchers, Alzheimer’s Research UK stated.

More For You

Pharmacist handing medicine to patient, NHS prescription cost freeze debate

Prescription charge will remain at £9.90

Pic credit: iStock

NPA calls for end to prescription charge after freeze announcement

The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.

Patients will continue paying £9.90 to collect their medication from a pharmacy.

Keep ReadingShow less
RPS launches new prescribing development programme for pharmacists

From 2026, every newly qualified pharmacist will be an independent prescriber

gettyimages

RPS unveils new training programme to enhance pharmacists’ prescribing skills

The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.

Keep ReadingShow less
Varenicline promotes nicotine vaping cessation in young people

Researchers warn that e-cigarette use can increase risk for nicotine addiction,uptake of combusted tobacco and other substance use.

gettyimages

Anti-smoking pill varenicline may help young people quit vaping, new study suggests

Varenicline — a daily pill already offered through NHS Stop Smoking Services — could also support young people in quitting vaping, new research has suggested.

The medication, proven to be more effective than nicotine replacement gums or patches for smoking cessation, was shown to significantly boost vaping abstinence when combined with behavioural counselling in adolescents and young adults.

Keep ReadingShow less
Relying on blue inhalers alone can worsen asthma symptoms, warns MHRA

Patients are advised to use their preventer inhaler regularly, even if their asthma feels under control.

Pic credit: gettyimages

Overuse of blue inhalers can increase risk of severe asthma attacks, warns MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding asthma patients to use their preventer (anti-inflammatory) inhalers regularly as prescribed, rather than relying solely on their blue inhalers, also referred to as reliever inhalers.

“Without regular use of a preventer inhaler, symptoms could worsen and increase the risk of severe asthma attacks,” the MHRA warned.

Keep ReadingShow less
13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less